Core Points - Kyowa Kirin International has appointed Julie Dehaene-Puype as President for the Region, effective November 1, 2025 [1] - Julie Dehaene-Puype succeeds Jeremy Morgan, who has been serving as President for the International Region since 2023 [1] - Jeremy Morgan will transition to an advisory role within the business following his tenure [1]

Group 1 - European companies are demonstrating remarkable adaptability to U.S. tariff barriers, with a Goldman Sachs portfolio of affected European stocks outperforming the market by approximately 6% in October, double the gain of the Stoxx Europe 600 index [1] - Major European firms like Hermès, Unilever, and Galderma Group AG attribute their better-than-expected performance and raised guidance to strong demand in the U.S. market [1][2] - The frequency of the term "tariff" in earnings calls is decreasing, indicating that corporate management's concerns about tariffs are diminishing [1] Group 2 - The U.S. market has become a key growth driver for many European companies, with Hermès reporting a 14.1% sales increase in its regional markets, and Unilever crediting strong North American demand for its sales performance [2] - Galderma raised its full-year guidance based on strong U.S. sales, while other companies like Haleon Plc and Stellantis also reported unexpected sales growth in North America [2] Group 3 - Companies are adapting to tariff challenges by cutting costs, adjusting production layouts, and increasing investments in the U.S. [3] - Pharmaceutical companies like Novartis and GSK are negotiating with the U.S. government for price reductions in exchange for future tariff exemptions, with AstraZeneca reaching an agreement in October [3] Group 4 - Despite overall optimism, the impact of tariffs is not uniform, with some companies like Rémy Cointreau and Pernod Ricard warning of weaker-than-expected recovery in specific markets [4] - Market sentiment is shifting towards the view that tariffs are manageable, although some analysts caution against premature conclusions regarding their impact [4][5]

We recently published 10 Stocks With Easy 20-40% Gains. Metsera Inc. (NASDAQ:MTSR) is one of the last week's best-performing stocks. Metsera saw its share prices jump by 20 percent week-on-week as investors gobbled up shares amid a billion-dollar bidding war between two pharmaceutical giants racing to gain a larger foothold in the booming weight-loss industry. This followed Novo Nordisk’s confirmation late last week that it submitted a new $8.5 billion offer to acquire Metsera Inc. (NASDAQ:MTSR), which w ...

We recently published 10 Stocks With Easy 20-40% Gains. Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the last week's best-performing stocks. Travere Therapeutics soared by 25.3 percent week-on-week as investors took heart from a stellar earnings performance and cues that the company would kick off the last month of the year on a strong note. Based on its financial statement on Thursday, Travere Therapeutics, Inc. (NASDAQ:TVTX) swung to a net income of $25.7 million in the third quarter of the year ...

Core Insights - Roche announced statistically significant and clinically meaningful results from the phase III ALLEGORY study of Gazyva®/Gazyvaro® (obinutuzumab) for adults with systemic lupus erythematosus (SLE), achieving its primary endpoint with a higher percentage of patients showing a minimum four-point improvement in SLE Responder Index 4 (SRI-4) at one year compared to standard therapy [1][2][4] Study Results - The ALLEGORY study met all key secondary endpoints, demonstrating significant benefits of Gazyva/Gazyvaro over standard therapy, including improvements in BICLA response, sustained corticosteroid control, sustained SRI-4, a six-point improvement in SLE disease activity score (SRI-6), and time to first flare [2][5] - The study involved approximately 300 participants, randomized to receive either Gazyva/Gazyvaro or placebo for up to 52 weeks, followed by an open-label period [9] Disease Impact - SLE affects over three million people globally, predominantly women aged 15 to 45, with a significant risk of developing lupus nephritis, a serious kidney complication, within five years of diagnosis [3][10][11] - Effective disease control can reduce flares and limit organ damage, potentially lowering the risk of developing lupus nephritis [3][11] Regulatory and Market Potential - Data from the study will be presented to health authorities, including the US FDA and the European Medicines Agency, with the aim of establishing Gazyva/Gazyvaro as a new standard of care for SLE [4][8] - If approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy targeting B cells in SLE, addressing a key driver of inflammation and disease activity [7][8] Broader Applications - Gazyva/Gazyvaro is also being investigated for use in children and adolescents with lupus nephritis and adults with membranous nephropathy, indicating Roche's ambition to lead in immune-mediated rheumatology and nephrology diseases [6][7]

Core Insights - Genentech, a member of the Roche Group, announced significant results from the Phase III ALLEGORY study of Gazyva (obinutuzumab) for adults with systemic lupus erythematosus (SLE) [1] Study Results - The study met its primary endpoint, demonstrating a higher percentage of patients achieving a minimum four-point improvement in SLE Responder Index 4 (SRI-4) at one year (52 weeks) with Gazyva [1]

Core Insights - Roche announced statistically significant and clinically meaningful results from the phase III ALLEGORY study of Gazyva®/Gazyvaro® (obinutuzumab) for adults with systemic lupus erythematosus (SLE), demonstrating a higher percentage of patients achieving a minimum four-point improvement in SLE Responder Index 4 (SRI-4) at one year compared to standard therapy [1][2] Group 1: Study Results - The ALLEGORY study met its primary endpoint, showing that Gazyva/Gazyvaro led to a higher percentage of patients achieving SRI-4 at 52 weeks [1] - All key secondary endpoints were also met, including statistically significant improvements in BICLA response, sustained corticosteroid control, sustained SRI-4, a six-point improvement in SLE disease activity score (SRI-6), and time to first flare [2][4] - The study involved approximately 300 participants, randomized to receive Gazyva/Gazyvaro or placebo for up to one year, followed by an open-label period [6] Group 2: Disease Context - Systemic lupus erythematosus (SLE) affects over three million people globally, primarily women aged 15 to 45, with a significant impact on women of color [2][7] - Around 50% of SLE patients progress to lupus nephritis within five years of diagnosis, which can lead to life-threatening kidney complications [2][7] Group 3: Future Implications - If approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy for SLE targeting B cells, addressing a key driver of inflammation and disease activity [4][5] - Roche aims to share the data with global health authorities, including the US FDA and the European Medicines Agency, to expedite the potential new standard of care [2][5] - The ALLEGORY study is the third positive phase III study for Gazyva/Gazyvaro in immune-mediated diseases, indicating its potential across a spectrum of autoimmune conditions [2][4]

Eli Lilly & Company (NYSE:LLY) ranks among the stocks with the best earnings growth for the next 5 years. Cantor Fitzgerald reaffirmed its Overweight rating and $925 price target for Eli Lilly & Company (NYSE:LLY) on October 17 following the exclusion of the company’s oral GLP-1 treatment, orforglipron, from the first group of medications to be granted Commissioner’s National Priority Vouchers (CNPV). Following the decision, Eli Lilly’s stock was under pressure in after-hours trading, which Cantor Fitzge ...

据医药魔方数据，2025前三季度中国License-out总金额共计920.3亿美元；信达与武田10月的交易金额最 高可达114亿美元，中国创新药对外授权总金额当前已突破1000亿美元。 此外，三生制药/辉瑞近期公告启动707两项全球三期临床，布局NSCLC和CRC。在今年5月，辉瑞以 12.50亿美元预付款+48亿美元里程碑付款+双位数百分比的销售分成引进三生制药的PD-1/VEGF双抗。 方正证券认为，信达生物、三生制药两大龙头国内、海外均持续超预期，随着BD的持续推进，中国创 新药深度参与全球产业链分成，长期价值凸显，继续看好创新药产业链。 创新药产业链相关ETF： CXO含量领先：港股通医疗ETF(520510)； 创新属性突出：恒生医药ETF(159892)； 聚焦器械龙头：医疗器械ETF(562600)。 ...

Core Points - The annual National Medical Insurance Negotiation ("Guo Tan") is taking place in Beijing from October 30, lasting about 4-5 days, with a focus on both essential drugs and innovative drugs [1] - A new "Commercial Insurance Innovative Drug Directory" has been established to address the high pricing of new drugs, which will begin negotiations on November 1 [1][2] - The negotiation process for the Commercial Insurance Innovative Drug Directory includes multiple stages such as company application, formal review, expert evaluation, and price negotiation [2] - The expected price reduction for drugs entering the Commercial Insurance Innovative Drug Directory is anticipated to be lower than the 50%-60% average seen in previous negotiations for basic medical insurance, possibly between 10%-30% [3][4] - A total of 79 new drugs have applied for both the basic medical insurance directory and the Commercial Insurance Innovative Drug Directory, indicating a broad coverage of diseases [5][6] Industry Insights - The Commercial Insurance Innovative Drug Directory aims to provide new opportunities for high-priced drugs that previously struggled to enter the basic medical insurance directory [9][10] - The directory is designed to encourage pharmaceutical companies to participate by offering policy commitments that provide greater flexibility in pricing and reimbursement [10][12] - The directory's implementation will require careful consideration of how to balance the interests of various stakeholders, including government departments, insurance companies, and pharmaceutical firms [13][14] - The inclusion of CAR-T therapies in the directory highlights the ongoing challenges and potential for high-priced innovative drugs within the healthcare system [7][8]